ARS Pharmaceuticals, Inc.
SPRY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.37 | -0.30 | 0.05 | -0.01 |
| FCF Yield | -4.76% | -2.31% | -3.31% | 4.04% |
| EV / EBITDA | -18.42 | -37.36 | -33.63 | 20.82 |
| Quality | ||||
| ROIC | -16.49% | -17.74% | -12.40% | 14.32% |
| Gross Margin | 74.80% | 68.29% | 86.28% | 99.00% |
| Cash Conversion Ratio | 0.92 | 0.88 | 1.20 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,582.06% | 700.50% | 424.53% | 307.65% |
| Free Cash Flow Growth | -19.17% | 2.91% | -197.92% | 385.49% |
| Safety | ||||
| Net Debt / EBITDA | 1.14 | 1.12 | 1.12 | -1.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.57 | 0.15 | 0.17 |
| Cash Conversion Cycle | 100.94 | 26.18 | 377.17 | -475.12 |